Literature DB >> 7018804

Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays.

S Rasmussen, M Damkjaer Nielsen, J Giese.   

Abstract

1. We have measured plasma concentrations of renin, renin substrate and angiotensins I and II as well as plasma renin activity in nine patients with severe or malignant hypertension during treatment with captopril, hydrochlorothiazide and propranolol. 2. On captopril and hydrochlorothiazide the plasma concentrations of renin substrate and angiotensin II decreased markedly, while renin and angiotensin I levels were increased. 3. The changes in renin substrate concentration suggest a consumption of substrate induced by an increased renin release. Further, the positive feedback of angiotensin II on hepatic renin substrate synthesis may be inhibited. 4. The sequential changes in renin release during captopril treatment should be monitored by measuring plasma renin concentration since plasma renin activity measurements will be profoundly influenced by the marked changes in plasma renin substrate concentration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018804     DOI: 10.1042/cs0600591

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

Review 1.  Biochemistry and pharmacology of the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Captopril: five years on.

Authors:  G P Hodsman; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-24

3.  Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

Authors:  A B Atkinson; A M Cumming; J J Brown; R Fraser; B Leckie; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

4.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

5.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

Authors:  C Richer; B Giroux; P F Plouin; B Maarek; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

6.  Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Deckert; J Giese; N J Christensen; L Bent-Hansen; M D Nielsen
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

7.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Enalapril in the treatment of hypertension with renal artery stenosis.

Authors:  G P Hodsman; J J Brown; A M Cumming; D L Davies; B W East; A F Lever; J J Morton; G D Murray; I Robertson; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.